03 Profile
Hansard to 12 November 2026 · 31,484 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Academic · Heart disease & stroke
Sanjiv Shah
M.D., principal investigator of the Level trial, Northwestern University
Quoted in the press, across 1 topic since 10 Aug 2026
02 Quoted on · 1 of 29 topics
Sanjiv Shah: key facts
- Kind of voice
- Academic
- Role
- M.D., principal investigator of the Level trial, Northwestern University
- Quoted on
- Heart disease & stroke
- Press coverage
- Quoted in the press
- Most recently quoted
- 10 Aug 2026
04 On the record · press
What Sanjiv Shah has said
- fiercepharma.com
Where Sanjiv Shah has been quoted
- Unapproved in US for decades, levosimendan stumbles in phase 3 as Tenax eyes narrow FDA pathfiercepharma.com · 10 Aug 2026
How we found the articles that name Sanjiv Shah: we searched news for these terms.
- heart disease
- cardiovascular
- stroke
- cardiac
- heart attack
- stroke rehabilitation
Also searched with “heart disease” in each of 8 national papers, and in the Guardian by editor tag, and in trade press by category. Every term for Heart disease & stroke
Verbatim
“In my opinion, a drug that lowers wall stress and modifies cardiac structure and function this robustly is likely to be disease-modifying”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
- Heart Charity Calls for National Strategy to Prevent Sudden DeathsCharity Today News
- Stroke treatment callsDnG24
- Stopping GLP-1s linked to twice the risk of heart attack, stroke or death in type 2 diabetesThe Pharmaceutical Journal
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 12 Nov 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.